Combination Therapy and Appropriate Dosing to Target KRAS in Colorectal Cancer
N Engl J Med
.
2023 Dec 7;389(23):2197-2199.
doi: 10.1056/NEJMe2311611.
Author
Rona Yaeger
1
Affiliation
1
From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
PMID:
38055257
DOI:
10.1056/NEJMe2311611
No abstract available
Publication types
Editorial
MeSH terms
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / genetics
Combined Modality Therapy
Humans
Proto-Oncogene Proteins p21(ras)* / genetics
Substances
Proto-Oncogene Proteins p21(ras)
KRAS protein, human